Status:

TERMINATED

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Diastolic Dysfunction

Lead Sponsor:

Bayer

Conditions:

Hypertension, Pulmonary

Ventricular Dysfunction, Left

Eligibility:

All Genders

18-90 years

Phase:

PHASE2

Brief Summary

The aim of this study is to assess whether single oral doses of Riociguat safely improve the cardiovascular function in patients with pulmonary hypertension associated with left ventricular diastolic ...

Eligibility Criteria

Inclusion

  • Male and female patients with symptomatic pulmonary hypertension due to left ventricular diastolic dysfunction

Exclusion

  • Types of pulmonary hypertension other than group 2.2 of Dana Point Classification

Key Trial Info

Start Date :

July 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2012

Estimated Enrollment :

39 Patients enrolled

Trial Details

Trial ID

NCT01172756

Start Date

July 1 2010

End Date

October 1 2012

Last Update

November 4 2014

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Graz, Styria, Austria, 8020

2

Graz, Styria, Austria, 8036

3

Linz, Upper Austria, Austria, 4010

4

Vienna, Vienna, Austria, 1090